Walz P H, Montgomery T, Passler T, Riddell K P, Braden T D, Zhang Y, Galik P K, Zuidhof S
Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL 36849.
Maple Row Dairy Farm, Saranac, MI 48881.
J Dairy Sci. 2015 Dec;98(12):8753-63. doi: 10.3168/jds.2015-9760. Epub 2015 Oct 9.
The objective of this randomized clinical trial was to compare the effect of revaccination in primiparous dairy cows with modified live viral (MLV) or killed viral (KV) vaccines containing bovine viral diarrhea virus (BVDV) and bovine herpesvirus-1 (BoHV-1) on (1) pregnancy rate following estrus synchronization-timed artificial insemination (TAI), (2) serum progesterone concentrations, and (3) serum neutralizing antibody titers at revaccination and at TAI. Primiparous dairy cows (n=692) that had been previously vaccinated with 4 doses of MLV vaccine as calves or heifers were randomized to receive either an MLV or a KV vaccine between 21 and 28 d in milk and 17 d before initiation of a double-Ovsynch-TAI protocol. Serum was collected within the double-Ovsynch protocol for determination of progesterone concentrations, and at vaccination and TAI for serum neutralizing antibody titers. Ultrasound pregnancy determinations were made at 30 and 60 d after TAI. No differences in pregnancy rates were observed between cows receiving MLV vaccine (44%; n=326) or KV vaccine (43%; n=336). No differences were observed in serum progesterone concentrations during a double-Ovsynch-TAI protocol between cows receiving MLV and KV vaccines. No differences were observed in BVDV 1 or BVDV 2 antibody titers at vaccination and TAI between cows receiving MLV or KV vaccine; however, BoHV-1 antibody titers were greater at TAI in cows receiving KV vaccine. Overall response to vaccination-defined as the percent of all individual cows that had any detectable increase in antibody titer from vaccination to TAI-was 39% for BVDV 1, 45% for BVDV 2, and 61% for BoHV-1. In this research, use of an MLV vaccine did not impede reproduction when revaccination was performed between 21 and 28 DIM and just before enrollment in an estrus synchronization-TAI program in primiparous dairy cows; however, response to vaccination as defined by increases in virus-specific antibody titers could be considered less than ideal for this population of cattle.
这项随机临床试验的目的是比较初产奶牛再次接种含有牛病毒性腹泻病毒(BVDV)和牛疱疹病毒1型(BoHV-1)的改良活病毒(MLV)或灭活病毒(KV)疫苗对以下方面的影响:(1)同期发情定时人工授精(TAI)后的妊娠率;(2)血清孕酮浓度;(3)再次接种时和TAI时的血清中和抗体滴度。将之前作为犊牛或小母牛接种过4剂MLV疫苗的初产奶牛(n = 692头)随机分为两组,在产奶21至28天且在开始双Ovsynch-TAI方案前17天,分别接受MLV疫苗或KV疫苗。在双Ovsynch方案内采集血清以测定孕酮浓度,在接种疫苗时和TAI时采集血清以测定血清中和抗体滴度。在TAI后30天和60天进行超声妊娠检测。接受MLV疫苗的奶牛(44%;n = 326头)和接受KV疫苗的奶牛(43%;n = 336头)之间的妊娠率没有差异。在双Ovsynch-TAI方案期间,接受MLV和KV疫苗的奶牛血清孕酮浓度没有差异。接受MLV或KV疫苗的奶牛在接种疫苗时和TAI时的BVDV 1或BVDV 2抗体滴度没有差异;然而,接受KV疫苗的奶牛在TAI时的BoHV-1抗体滴度更高。疫苗接种的总体反应(定义为从接种疫苗到TAI抗体滴度有任何可检测到升高的所有个体奶牛的百分比),BVDV 1为39%,BVDV 2为45%,BoHV-1为61%。在本研究中,当在初产奶牛产奶21至28天且恰好在进入同期发情-TAI程序之前进行再次接种时,使用MLV疫苗不会妨碍繁殖;然而,以病毒特异性抗体滴度升高定义的疫苗接种反应对于这群奶牛而言可能被认为不太理想。